Abstract
Thrombopoietin (TPO) regulates megakaryopoiesis and the generation of platelets. Recombinant TPO has been investigated in clinical studies for use in thrombocytopenia with limited success. A new peptibody, AMG 531, has been shown to increase platelet counts in preclinical and Phase 1 and Phase 2 studies and to be generally safe and tolerable in those studies.
Copyright (c) 2006 Wiley-Liss, Inc.
MeSH terms
-
Animals
-
Carrier Proteins / administration & dosage
-
Carrier Proteins / immunology
-
Carrier Proteins / therapeutic use*
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
Dose-Response Relationship, Drug
-
Humans
-
Placebos
-
Platelet Count
-
Purpura, Thrombocytopenic, Idiopathic / drug therapy*
-
Purpura, Thrombocytopenic, Idiopathic / immunology
-
Randomized Controlled Trials as Topic
-
Receptors, Fc / administration & dosage
-
Receptors, Fc / immunology
-
Receptors, Fc / therapeutic use*
-
Recombinant Fusion Proteins
-
Thrombopoiesis / drug effects*
-
Thrombopoiesis / immunology
-
Thrombopoietin
Substances
-
Carrier Proteins
-
Placebos
-
Receptors, Fc
-
Recombinant Fusion Proteins
-
Thrombopoietin
-
romiplostim